severe case of thrombotic microangiopathy with a delayed diagnosis of atypical haemolytic uraemic syndrome successfully managed with eculizumab
Clicks: 188
ID: 139968
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
188 views
23 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #21 of 42 articles by views in indian journal of dental research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objectives: To describe the diagnosis and treatment of a severely ill patient presenting with thrombotic microangiopathy (TMA) of unknown cause.
Case presentation: An adult female presented to intensive care with abdominal pain and haemorrhagic shock, requiring reanimation.
Results: Features of TMA were present, but initial plasma exchange was ineffective. Treatment with the anti-C5 antibody, eculizumab, improved laboratory parameters and organ function, albeit slowly. Eculizumab remains effective and well tolerated after 30 months of treatment.
Conclusion: This case demonstrates the complexities and importance of early identification of atypical haemolytic uraemic syndrome in patients presenting with TMA.
| Reference Key |
aresmouk2015europeansevere
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Duaa Aresmouk |
| Journal | indian journal of dental research |
| Year | 2015 |
| DOI |
10.12890/2015_000180
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.